Comparable survival outcome with anti-EGFR therapy in any treatment line in left-sided metastatic colorectal cancer
While earlier line use confers longer PFS, OS remains similar regardless of the timing of anti-EGFR therapy. These findings support the introduction of anti-EGFR agents at any line when feasible, highlighting that ensuring access may be more important than timing in treatment sequencing.
Authors
- Krittiya Korphaisarn (ORCID: https://orcid.org/0000-0001-5739-0175)
- Anita Archwamety (ORCID: https://orcid.org/0000-0002-2003-9127)
- Charuwan Akewanlop (ORCID: https://orcid.org/0000-0003-1022-3745)
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.21037/jgo-2025-811
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00